Concepedia

Philipp Haselmayer

PH

Statistics

Publications

14

Citations

1.1K

H-Index

13

Active since

2006

Affiliations

Merck KGaA, Darmstadt (Germany)(Current)

Johannes Gutenberg University Mainz

University of Tübingen

Ono Pharmaceutical (United States)

Merck Serono S.A. (Switzerland)

Philipp Haselmayer is an author at Merck KGaA, Darmstadt (Germany) specializing in immunology, life sciences, and inflammation.

ORCID

Publications per year

2006–2020

14

Publications

14

TREM-1 ligand expression on platelets enhances neutrophil activation

Philipp Haselmayer, Ludger Große‐Hovest, Philipp von Landenberg et al. · Blood · 2007 · 209 citations · Full text

, , +14

Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

Andrew T. Bender, A.S. Gardberg, Albertina Pereira et al. · Molecular Pharmacology · 2017 · 188 citations

, , +17

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models

Philipp Haselmayer, Montserrat Camps, Lesley Liu‐Bujalski et al. · The Journal of Immunology · 2019 · 148 citations · Full text

, , +17

Interaction of TLR2 and TLR4 Ligands with the N-terminal Domain of Gp96 Amplifies Innate and Adaptive Immune Responses

Tobias Warger, Nobert Hilf, Gerd Rechtsteiner et al. · Journal of Biological Chemistry · 2006 · 136 citations · Full text

, , +16

Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease

Sebastian Torke, Roxanne Pretzsch, Darius Häusler et al. · Acta Neuropathologica · 2020 · 100 citations · Full text

, , +17

1–5 of 14